Castleark Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Castleark Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-24,706	Closed	-$5.36M	–	326
2023 Q2	$5.36M	Sell	24,706 -230	-0.9%	-$49.3K	0.24%	97
2023 Q1	$4.53M	Hold	24,936	–	–	0.22%	108
2022 Q4	$4.9M	Buy	24,936 +13,690	+122%	+$2.94M	0.26%	97
2022 Q3	$2.53M	Buy	+11,246	New	+$2.28M	0.14%	141
2022 Q1	–	Sell	-23,950	Closed	-$3.14M	–	371
2021 Q4	$3.14M	Buy	+23,950	New	+$3.1M	0.12%	162

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Castleark Management's KRTX Position: Q3 2023 in Review

Castleark Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 24,706 shares — an estimated $5.36M sold.

Castleark Management first reported a position in KRTX in Q4 2021 and held it in 5 quarters. The position peaked at $5.36M in Q2 2023. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

Castleark Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Castleark Management sold 24,706 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $5.36M.
Castleark Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
Castleark Management's Karuna Therapeutics, Inc. Common Stock position peaked at $5.36M in Q2 2023.
256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Castleark Management's 13F filing for Q3 2023, filed 15 Nov 2023.